iiinova — where your digital self keeps evolving

Reposted by Sarat Chandarlapaty

Elizabeth McKenna @elizsmckenna.bsky.social · 10/11/2025

Now online in Cancer Discovery @aacrjournals.bsky.social: Trastuzumab Deruxtecan (T-DXd) Resistance via Loss of HER2 Expression and Binding - by Wanyi Chen, @joshdragomd.bsky.social, @saratchandarlapaty.bsky.social, and colleagues doi.org/10.1158/2159... @mskcancercenter.bsky.social

065

Reposted by Sarat Chandarlapaty

Josh Drago, MD, MS @joshdragomd.bsky.social · 10/11/2025

ADC resistance is likely heterogeneous, and the phenomena above may explain only a portion of cases. But these early clues can inform prospective trail efforts, as well as ADC sequencing strategies. There is much more to come!

112

Sarat Chandarlapaty @saratchandarlapaty.bsky.social · 04/06/2025

Published online today - work led by Yanyan Cai: Inhibition of NR2F2 restores hormone therapy response to endocrine refractory breast cancers | Science Translational Medicine www.science.org/doi/10.1126/...

science.org

Inhibition of NR2F2 restores hormone therapy response to endocrine refractory breast cancers

NR2F2 modulates the ER cistrome, coregulator interactions, and chromatin accessibility to promote endocrine resistance in ER+ breast cancer.

083

Reposted by Sarat Chandarlapaty

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 16/05/2025

🚨 NEW in @natgenet.nature.com: MSK's Dr. Sarat Chandarlapaty and colleagues investigates how APOBEC3 #mutagenesis drives therapy resistance in #BreastCancer. Learn more: www.nature.com/articles/s41...

082

Reposted by Sarat Chandarlapaty

Avantika Gupta @avantikagupta.bsky.social · 28/04/2025

@saratchandarlapaty.bsky.social expertly summarizing our work on how underlying genomic instability in breast cancer leads to therapy resistance leaving with key ideas on how we might target them! Come see me expand on the role of APOBEC3 mutagenesis in these processes tomorrow morning at #AACR25!

021

Reposted by Sarat Chandarlapaty

Avantika Gupta @avantikagupta.bsky.social · 13/12/2024

A hugely collaborative team effort under the mentorship of @saratchandarlapaty.bsky.social @mskcancercenter.bsky.social

173

Sarat Chandarlapaty @saratchandarlapaty.bsky.social · 13/12/2024

Fabulous plenary from Dr. Pedram Razavi #sabcs2024 on robust and innovative ai models to separate cdk4/6i responders from non-responders.

071

Sarat Chandarlapaty @saratchandarlapaty.bsky.social · 12/12/2024

Fantastic presentation #SABCS by @avantikagupta.bsky.social on apobec3 in breast cancer. Demonstrating the role of this process in promoting therapy resistance.

1144

Reposted by Sarat Chandarlapaty

Avantika Gupta @avantikagupta.bsky.social · 12/12/2024

Congratulations to @caiy0219.bsky.social for an excellent poster presentation today! 👏🏽 Also, so happy to be reunited with @reikudo.bsky.social to represent the translational team in @saratchandarlapaty.bsky.social’s lab at #SABCS2024!

052

Sarat Chandarlapaty @saratchandarlapaty.bsky.social · 11/12/2024

Super plenary from Komal Jhaveri on imlunestrant #sabcs Congrats to her and the Ember-3 trial authors for developing this SERD (and combo with Abema)

082

Reposted by Sarat Chandarlapaty

Tatiana Prowell, MD @tmprowell.bsky.social · 12/11/2024

NEW #Oncology: EGFR expression mediates resistance to T-DXd (EGFR overexpression ⬇️ HER2 homodimerization & HER2/ADC internalization) Combining with EGFR mAbs restored HER2/ADC trafficking & ⬆️ activity in nonclinical models #DrugDevelopment #OncoSky www.cell.com/cell-reports...

cell.com

EGFR-directed antibodies promote HER2 ADC internalization and efficacy

Gupta et al. demonstrate that high EGFR expression mediates resistance to HER2 antibody drug conjugates (ADCs) including trastuzumab deruxtecan (T-DXd) by limiting HER2/ADC internalization. The additi...

35213